In 1980, Sarepta Therapeutics began its journey as AntiVirals Inc., founded by Dwight Weller and Milton Zuker with a vision for advancing antisense chemistry. The company evolved significantly over the decades - transforming through name changes and strategic pivots - from its initial focus on antiviral therapies to becoming a pioneering force in precision genetic medicine for rare diseases. This evolution wasn't just corporate restructuring; it was a response to a critical gap in treating devastating conditions that had long been overlooked by traditional pharmaceutical approaches. Today, Sarepta stands at the forefront of genetic medicine, having launched four FDA-approved therapies including the first-ever gene therapy for Duchenne muscular dystrophy, representing hope for patients who previously had none.
Sarepta is a global biotechnology company on an urgent mission: to engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. With headquarters in Cambridge, Massachusetts, and operations spanning the United States, Ireland, Switzerland, and the United Kingdom, the team is pioneering RNA-targeted therapeutics and gene therapies. Their focus centers on Duchenne muscular dystrophy and limb-girdle muscular dystrophy - debilitating conditions affecting thousands worldwide. Beyond drug development, Sarepta demonstrates deep commitment to patients through programs like SareptAssist, which provides personalized support navigating treatment access, and Route 79, a scholarship program supporting the educational goals of students living with Duchenne. The company's culture is built on values that prioritize patients, urgency, and scientific excellence, driving them daily to transform genetic understanding into life-changing treatments.
